Page 2515 - Williams Hematology ( PDFDrive )

2486 Index Index 2487

R Ral GTPases, 1883 Ras/Raf/MAPK pathway gene mutations,
R207H, 1838 Random-label methods, for red cell life span 232t, 233t
Rab, 1065f, 1849 measurement, 495–496, 496f Ras/Raf/MEK/ERK cascade, 237
Rab GTPases, 1883 RANK (receptor activator of NF-κB), 1606, RB, 238, 1710
Rac (Rac), 237, 1841 1713 RB1, 232t, 234t, 1464, 1653, 1736, 1737
Rac-2 deficiency, 1020t RANKL (receptor activator of NF-κB ligand), RB–E2F complex, 217, 217f
Rac GTPases, 1883 1077f, 1713, 1737, 1738f, 1739f R binder. See Haptocorrin
RACK1 (receptor of activated protein kinase RANTES (CCL5), 1607, 1852f, 1855, 2286 RBM8A, 2061
C), 487 Rapamycin, 1220 RB (Rb) proteins, 217, 217f, 1444
R-ACVBP, for diffuse large B-cell lymphoma, Rap GTPases, 1883 RCF (ristocetin cofactor) activity, 1988, 1991
1630 RAPH. See CD151 R-CHOP regimen
RAD21, 1346t, 1352 Raph blood group, 2332t for Castleman disease, 1250
Rad-57, 792 RAPH phenotype, 2343 for diffuse large B-cell lymphoma, 1628,
null
Radial nuclear segmentation, 23 Rapoport Luebering shunt, 692 1628t, 1629t, 1630
Radiation exposure Rare bleeding disorders (RBDs), 2133–2145 for follicular lymphoma, 1645t, 1646–1647,
acute lymphoblastic leukemia and, 1507 classification, 2134 1646t, 1649
acute myelogenous leukemia and, 1374 combined deficiency of factors V and VIII, for HIV-associated lymphoma, 1245
aplastic anemia and, 518 2139–2140 for intravascular large B-cell lymphoma,
chronic lymphocytic leukemia and, 1528 factor V deficiency. See Factor V deficiency 1636
chronic myelogenous leukemia and, 1438 (parahemophilia) for mantle cell lymphoma, 1656, 1656f,
hemolytic anemia and, 811 factor VII deficiency. See Factor VII 1657t, 1658t
lymphoma and, 1573 deficiency for posttransplant lymphoproliferative
myelodysplastic syndromes and, 1342, factor X deficiency. See Factor X deficiency disorders, 1636
1345 factor XI deficiency. See Factor XI for primary testicular lymphoma,
primary myelofibrosis and, 1319 deficiency 1634
Radiation therapy factor XIII deficiency. See Factor XIII for T-cell-histiocyte-rich large B-cell
for acute lymphoblastic leukemia, 1517 deficiency lymphoma, 1637
for bone pain in myeloma, 1756 gene mutations, 2134–2135, 2135t for Waldenström macroglobulinemia,
for chronic lymphocytic leukemia, 1540 incidence, 2133, 2134t 1794–1795
for chronic myelogenous leukemia, 1459 laboratory features, 2133–2134 R-CP regimen, for Waldenström
cranial, 1519t, 1520 prothrombin deficiency. See Prothrombin macroglobulinemia, 1795
for diffuse large B-cell lymphoma (factor II) deficiency R-CVP regimen
with CHOP, 1628 treatment, 2135, 2136t for follicular lymphoma, 1645t, 1646–1647,
with R-CHOP, 1628 in women, 2135 1646f, 1646t, 1649
for follicular lymphoma, 99. RARS (refractory anemia, with ring for mantle cell lymphoma, 1656
for Hodgkin lymphoma, 1248, 1611, 1613, sideroblasts), 178, 1343, 1343t, for Waldenström macroglobulinemia, 1795
1614 1349 RDAs. See Recommended daily allowances
for mantle cell lymphoma, 1656–1657 RARS-T (refractory anemia, with ring (RDAs)
for ocular/intraocular lymphoma, 1581 sideroblasts with thrombocytosis), R-DHAP regimen, for diffuse large B-cell
for primary myelofibrosis, 1330 178, 1343, 1343t, 1349, 1352 lymphoma, 1631
Radioactive phosphorus, 1298t, 1299, 1313t, RAR-α, 1390–1391 RDW (red cell distribution width), 14
1314 Ras, 238 Reactive hypereosinophilia, 959
Radioimmunoconjugates, 346, 360 RAS (RAS) Reactive leukocytosis, 1450
Radioimmunotherapy in acute myelogenous leukemia, 1398 Reactive lymphocytes, 23, 1203f, 1264, 1264f
adverse effects, 1647 in cell growth, 192 Reactive nitrogen intermediates, 286–287,
for diffuse large B-cell lymphoma, 1632 in cellular senescence, 132 286t
for follicular lymphoma, 1647, 1649 in chronic myelogenous leukemia, 1443, Reactive oxygen intermediates, 286, 286t
Radionuclide lung scanning, 2271 1471 Reactive oxygen species (ROS), 195–196,
RAEB (refractory anemia with excess blasts). in myeloma, 1710, 1735, 1736t, 1737 1663
See Oligoblastic myelogenous in primary myelofibrosis, 1320, 1321 Reactive thrombocytosis, 1310, 1312t,
leukemia (refractory anemia with RAS (renin-angiotensin system), 487 2035–2037
excess blasts) Rasburicase Reaginic antibody, 1162
RAG1/2, 1164, 1214t, 1218, 1219 in G6PD deficiency, 712 Receiver operator characteristic curves, 635,
Rag-1/Rag-2 complex, 1164, 1166–1167, for hyperuricemia, 1394, 1450, 1514, 1675 635f
1166f, 1168 Ras family proteins, 230, 237 Receptor activator of NF-κB (RANK), 1606,
Rai clinical staging system, 1533t Ras GTPases, 1882–1883 1713

Kaushansky_index_p2393-2506.indd 2486 9/21/15 3:22 PM